---
title: Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage
  Prostate Cancer-Combination Strategies
date: '2023-10-20'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37861915/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231020180831&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'PURPOSE OF REVIEW: [^(177)Lu]Lu-PSMA-617 is a radiopharmaceutical that
  emits beta-minus radiation and targets prostate-specific membrane antigen (PSMA)-positive
  prostate cancer. Despite its clinical success, there are still patients not showing
  sufficient response rates. This review compiles latest studies aiming at therapy
  improvement in [^(177)Lu]Lu-PSMA-617-naïve and -resistant patients by alternative
  or combination ...'
disable_comments: true
---
PURPOSE OF REVIEW: [^(177)Lu]Lu-PSMA-617 is a radiopharmaceutical that emits beta-minus radiation and targets prostate-specific membrane antigen (PSMA)-positive prostate cancer. Despite its clinical success, there are still patients not showing sufficient response rates. This review compiles latest studies aiming at therapy improvement in [^(177)Lu]Lu-PSMA-617-naïve and -resistant patients by alternative or combination ...